Drug intelligence / Profile preview

obinepitide

Development stage
Unknown
Lead developer
7TM Pharma
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Obinepitide is a synthetic peptide drug designed as an analogue of two natural human hormones, peptide YY (PYY) and pancreatic polypeptide. Both hormones are released during meals and act as satiety signals from the gastrointestinal tract to the central nervous system, helping regulate food intake and appetite. Obinepitide combines the properties of both PYY and pancreatic polypeptide into a single molecule, acting as a dual agonist at neuropeptide Y2 (Y2) and neuropeptide Y4 (Y4) receptors with high potency. This dual action is intended to suppress appetite more effectively than targeting either receptor alone. In preclinical studies, obinepitide demonstrated superior long-term weight reduction compared to PYY3–36 alone. The drug was developed primarily for obesity treatment but has not reached regulatory approval[1][2][3][4][5].

Other names
Obinepitide [INN](34-L-glutamine)pancreatic hormone (human)OBINEPITIDE
02

Targets

NPY2R (Neuropeptide Y receptor subtype 2)NPY4R (Neuropeptide Y receptor Y4)

Beyond the preview

Go deeper on obinepitide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on obinepitide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call